Results 51 to 60 of about 1,250,392 (346)

Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald, Michela Guglieri, Dragana Vučinić, Gyula Acsadi, John F. Brandsema, Claudio Bruno, Erika L. Finanger, Amy Harper, Mercedes Lopez Lobato, Riccardo Masson, Nuria Muelas, Francina Munell, Yoram Nevo, Yann Péréon, Han Phan, Valeria A. Sansone, Mariacristina Scoto, Tracey Willis, Richard S. Finkel, Krista Vandenborne, Sara Cazzaniga, Silvia Montrasio, Federica Alessi, Paolo Bettica, Eugenio Mercuri, for the Givinostat Study 51 Investigators, the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators, the ImagingDMD Investigators, Enrico Bertini, Giacomo Pietro Comi, Eugenio Maria Mercuri, Giuseppe Vita, Sonia Messina, Claudio Bruno, Riccardo Masson, Valeria Sansone, Nathalie Goemans, Liesbeth De Waele, Laurent Servais, Teresa Gidaro, Odile Boespflug‐Tanguy, Yann Péréon, Jessika Johannsen, Astrid Blaschek, Ulrike Schara‐Schmidt, Erik Niks, Imelda de Groot, Saskia Houwen‐van Opstal, Andres Nascimento, Juan Jesus Vilchez, Nuria Muelas, Francina Munell, Marcos Madruga Garrido, Mercedes Lopez Lobato, Michaela Guglieri, Tracey Willis, Stefan Spinty, Daniel Hawcutt, Mariacristina Scoto, Jean K. Mah, Laura McAdam, Kathryn Selby, Katherine Mathews, Craig McDonald, Craig Zaidman, Barry Byrne, John Brandsema, Gyula Acsadi, Chamindra Laverty, Amy Harper, Erika Finanger, Han Phan, Yoram Nevo, Vedrana Milic Rasic, Dragana Vucinic   +74 more
wiley   +1 more source

Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease [PDF]

, 2002
In a double blind randomised controlled trial, 30 infants with chronic lung disease received fluticasone propionate or placebo for one year. There were no significant differences between treatment groups in the incidence of any day or night time symptoms
Beresford, M.W., Primhak, R.A., Shaw, N.J., Subhedar, N.V.   +3 more
core   +2 more sources

Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis

Arthritis Care &Research, Accepted Article.
Background Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our
Shivani Garg, Brad Rovin, Brad C. Astor, Tripti Singh, Fauzia Hollnagel, Megan Kuik, Lexie Kolton, Callie Saric, S. Sam Lim, Christie M. Bartels   +9 more
wiley   +1 more source

Moving to the Double-Blind Review System

Journal of Intelligence, 2015
The Journal of Intelligence presently has a single-blind peer review system, unlike most other journals in the social sciences, where the double-blind peer review prevails. The choice between the two systems is not easy.
Paul De Boeck
doaj   +1 more source

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression [PDF]

, 2012
Background: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the efficacy of new psychopharmacological interventions in the treatment of major depression.
A Cipriani, A Cipriani, A Hrobjartsson, A Loh, Andrea Pfennig, BR Rutherford, CP Gross, DE Moerman, DL Sackett, EA Largent, Emanuel Severus, F Seemuller, FG Miller, Florian Seemüller, G Parker, GI Papakostas, H Brody, H Brody, Hans-Jürgen Möller, HJ Moller, HJ Moller, HJ Moller, HU Wittchen, HV Krell, J Odgaard-Jensen, L Colloca, L Colloca, M Sinyor, MA Posternak, ME Wechsler, Michael Bauer, Michael Berger, Michael Obermeier, Michael Riedel, R Jones, RE Drake, RW Lam, Sandra Dittmann, SB Patten, SH Kennedy, Sophia Frangou, SR Wisniewski, U Hegerl, U Hegerl   +43 more
core   +3 more sources

Global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis burden, 1990–2021

Arthritis Care &Research, Accepted Article.
Objective This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods Age‐standardized years lived with disability rate for site‐specific OA across 204 countries/territories were obtained from the Global Burden of Diseases Study (GBD) 2021.
Haowei Chen, Lei Si, David J Hunter, Lei Zhang, Zhe‐Sheng Chen, Xiaomeng Wang, Vicky Duong, Zhounan Zhou, Peihua Cao, Han Cen, Su'an Tang, Tianyu Chen, Houjun Xue, Zhaohua Zhu, Changhai Ding   +14 more
wiley   +1 more source

Forms of identity. Ireland, Language and Translation [PDF]

, 2014
Questo volume include una serie di articoli su lingua, traduzione e identit\ue0 in Irlanda raccolti con un 'call for paper' internazionale e selezionati con un processo di 'double-peer blind review'
Monica Randaccio
core   +2 more sources

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Randomized, Controlled Study of Adderall XR in ADHD

Pediatric Neurology Briefs, 2002
The efficacy and safety of Adderall XR in the treatment of attention deficit/hyperactivity disorder and diurnal variation in responses were assessed by a multicenter, randomized, double-blind, parallel group, placebo-controlled trial at 47 sites, and ...
J Gordon Millichap
doaj   +1 more source

Heterogeneity of Rheumatoid Arthritis‐Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations with Disease Outcomes

Arthritis Care &Research, Accepted Article.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999‐2021. RA‐ILD patients were
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source